SimonMed Imaging has entered an agreement to purchase CureMetrix's cmAngio AI-powered mammography solution for its network of facilities around the U.S.

Announcing the deal, Dr. John Simon, CEO of SimonMed Imaging, said that technology must be readily available and affordable to make an impact on patient care, and that CureMetrix charges a rate that allows its customers to provide a "high-quality and high-impact" service.

cmAngio was cleared by the FDA last year to detect and localize Breast Arterial Calcifications (BAC) on mammograms. It's able to analyze both full-field digital mammography and digital breast tomosynthesis screening mammograms.
"Pricing is always the decision of our customers and we support their efforts to deliver our solutions to their customers at a rate that aligns with their patient demographics and corporate philosophy," Kevin Harris, president of CureMetrix, told HCB News. "With our SimonMed partnership, the final price point is set by our customers, and we take pride in helping provide accessibility and affordability to their patients."

Studies have shown that among women who undergo screening mammography, the prevalence of BAC ranges from 12 to 42.5%. However, according to an internal CureMetrix analysis based on data from 2008 to 2018, fewer than 5% of incidental findings of BAC on mammograms are reported.

SimonMed Imaging is one of the largest outpatient medical imaging providers and physician radiology practices in the country, operating in 10 states. It runs over 150 accredited facilities with ACR-RADSITE certification and employs more than 200 subspecialty-trained radiologists.

Artificial Intelligence Homepage